Skip to main content
Margriet den Boer on Muck Rack

Margriet den Boer

As seen in: BMJ Open, The Lancet, medRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Margriet den

Contact Margriet den, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India

|
By Shyam Sundar, Fabiana Alves, Koert Ritmeijer, Margriet den Boer
| medRxiv
S. Sundar has received consulting fees from Novartis Pharma AG. F. Alves and C. Forsyth are employed by Drugs for Neglected Diseases initiative (nonprofit organization). K. Ritmeijer and M. den Boer have no conflicts of interest to disclose. B. Hughes is employed by Novartis Pharmaceuticals UK Ltd and received stock options from Novartis Pharma AG. C. Zambles company (Lumanity) has been contracted and paid by Novartis Pharma AG for writing support and market research. K. Carter and G.
Open in Who Shared View Duplicates (33) Issue with article?

Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action

|
By Jorge Alvar, Margriet den Boer, Médecins Sans Frontières, Daniel Argaw Dagne
| The Lancet Verified
Summary East Africa is the world region most affected by visceral leishmaniasis, accounting for 45% of cases globally that were reported to WHO in 2018, with an annual incidence that is only slightly decreasing. Unlike southeast Asia, east Africa does not have a regional approach to achieving elimination of visceral leishmaniasis as a public health problem. The goal of the WHO 2021–30 Neglected Tropical Diseases road map is to reduce mortality caused by the disease to less than 1%.
Open in Who Shared Issue with article?

Exploring global and country-level barriers to an effective supply of leishmaniasis medicines and diagnostics in eastern Africa: a qualitative study

|
By Temmy Sunyoto, Julien Potet, Margriet den Boer, Artsen zonder Grenzen
| BMJ Open Verified
Qualitative research Research Exploring global and country-level barriers to an effective supply of leishmaniasis medicines and diagnostics in eastern Africa: a qualitative study Temmy Sunyoto1, Julien Potet2, Margriet den Boer3, Koert Ritmeijer3, Jose A R Postigo4, Raffaella Ravinetto1, Fabiana Alves5, Albert Picado6,7, Marleen Boelaert1 1 Public Health Department, Institute of Tropical Medicine, Antwerpen, Belgium 2 Medical Department, Médecins Sans Frontières Access Campaign, Paris, France...
Open in Who Shared Issue with article?
See all 3 articles